9月24日 - ** 药物开发商Vor Biopharma VOR.O股价盘前上涨7%至33.47美元
** 券商Stifel将股票评级从 "持有 "上调至 "买入"，称看好telitacicept在自身免疫疾病领域的前景
** 在该公司股票开始按拆分调整后的价格进行交易后，Stifel 将目标价定为 55 美元；之前的目标价为每股 30 美分
** 根据上周宣布的反向拆股，每 20 股 Vor 公司股票转换为一股股票
** 经纪公司称，泰利西塞普 "有可能成为同类最佳的 BAFF/APRIL 双拮抗剂"，理由是其机制和临床前景良好
** Telitacicept 已在中国获得三项监管批准，并计划再申请两项批准
** Stifel 目前预计泰利西赛普的峰值销售额约为 50 亿美元
** 截至上一交易日收盘，股价累计上涨 40
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.